From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past
Although melanoma remains the deadliest skin cancer, the current treatment has not resulted in the desired outcomes. Unlike chemotherapy, immunotherapy has provided more tolerable approaches and revolutionized cancer therapy. Although dendritic cell-based vaccines have minor side effects, the undesi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.623639/full |
id |
doaj-45f6c68bbf6542ee99b2ef15c8bd57ec |
---|---|
record_format |
Article |
spelling |
doaj-45f6c68bbf6542ee99b2ef15c8bd57ec2021-02-22T04:50:43ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-02-011210.3389/fimmu.2021.623639623639From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the PastMahdi Abdoli Shadbad0Mahdi Abdoli Shadbad1Khalil Hajiasgharzadeh2Afshin Derakhshani3Afshin Derakhshani4Nicola Silvestris5Nicola Silvestris6Amir Baghbanzadeh7Vito Racanelli8Behzad Baradaran9Behzad Baradaran10Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori “Giovanni Paolo II” of Bari, Bari, ItalyIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori “Giovanni Paolo II” of Bari, Bari, ItalyDepartment of Biomedical Sciences and Human Oncology, Aldo Moro University of Bari, Bari, ItalyImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Biomedical Sciences and Human Oncology, Aldo Moro University of Bari, Bari, ItalyImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranAlthough melanoma remains the deadliest skin cancer, the current treatment has not resulted in the desired outcomes. Unlike chemotherapy, immunotherapy has provided more tolerable approaches and revolutionized cancer therapy. Although dendritic cell-based vaccines have minor side effects, the undesirable response rates of traditional approaches have posed questions about their clinical translation. The immunosuppressive tumor microenvironment can be the underlying reason for their low response rates. Immune checkpoints and indoleamine 2,3-dioxygenase have been implicated in the induction of immunosuppressive tumor microenvironment. Growing evidence indicates that the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/Protein kinase B (PKB) (PI3K/AKT) pathways, as the main oncogenic pathways of melanoma, can upregulate the tumoral immune checkpoints, like programmed death-ligand 1. This study briefly represents the main oncogenic pathways of melanoma and highlights the cross-talk between these oncogenic pathways with indoleamine 2,3-dioxygenase, tumoral immune checkpoints, and myeloid-derived suppressor cells. Moreover, this study sheds light on a novel tumor antigen on melanoma, which has substantial roles in tumoral immune checkpoints expression, indoleamine 2,3-dioxygenase secretion, and stimulating the oncogenic pathways. Finally, this review collects the lessons from the previous unsuccessful trials and integrates their lessons with new approaches in RNA-modified dendritic cell vaccines. Unlike traditional approaches, the advances in single-cell RNA-sequencing techniques and RNA-modified dendritic cell vaccines along with combined therapy of the immune checkpoint inhibitors, indoleamine 2,3-dioxygenase inhibitor, and RNA-modified dendritic cell-based vaccine can overcome these auto-inductive loops and pave the way for developing robust dendritic cell-based vaccines with the most favorable response rate and the least side effects.https://www.frontiersin.org/articles/10.3389/fimmu.2021.623639/fulldendritic cellsimmunotherapymelanoma developmentimmune checkpointsIDORNA-modified dendritic cell vaccines |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mahdi Abdoli Shadbad Mahdi Abdoli Shadbad Khalil Hajiasgharzadeh Afshin Derakhshani Afshin Derakhshani Nicola Silvestris Nicola Silvestris Amir Baghbanzadeh Vito Racanelli Behzad Baradaran Behzad Baradaran |
spellingShingle |
Mahdi Abdoli Shadbad Mahdi Abdoli Shadbad Khalil Hajiasgharzadeh Afshin Derakhshani Afshin Derakhshani Nicola Silvestris Nicola Silvestris Amir Baghbanzadeh Vito Racanelli Behzad Baradaran Behzad Baradaran From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past Frontiers in Immunology dendritic cells immunotherapy melanoma development immune checkpoints IDO RNA-modified dendritic cell vaccines |
author_facet |
Mahdi Abdoli Shadbad Mahdi Abdoli Shadbad Khalil Hajiasgharzadeh Afshin Derakhshani Afshin Derakhshani Nicola Silvestris Nicola Silvestris Amir Baghbanzadeh Vito Racanelli Behzad Baradaran Behzad Baradaran |
author_sort |
Mahdi Abdoli Shadbad |
title |
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past |
title_short |
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past |
title_full |
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past |
title_fullStr |
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past |
title_full_unstemmed |
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past |
title_sort |
from melanoma development to rna-modified dendritic cell vaccines: highlighting the lessons from the past |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2021-02-01 |
description |
Although melanoma remains the deadliest skin cancer, the current treatment has not resulted in the desired outcomes. Unlike chemotherapy, immunotherapy has provided more tolerable approaches and revolutionized cancer therapy. Although dendritic cell-based vaccines have minor side effects, the undesirable response rates of traditional approaches have posed questions about their clinical translation. The immunosuppressive tumor microenvironment can be the underlying reason for their low response rates. Immune checkpoints and indoleamine 2,3-dioxygenase have been implicated in the induction of immunosuppressive tumor microenvironment. Growing evidence indicates that the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/Protein kinase B (PKB) (PI3K/AKT) pathways, as the main oncogenic pathways of melanoma, can upregulate the tumoral immune checkpoints, like programmed death-ligand 1. This study briefly represents the main oncogenic pathways of melanoma and highlights the cross-talk between these oncogenic pathways with indoleamine 2,3-dioxygenase, tumoral immune checkpoints, and myeloid-derived suppressor cells. Moreover, this study sheds light on a novel tumor antigen on melanoma, which has substantial roles in tumoral immune checkpoints expression, indoleamine 2,3-dioxygenase secretion, and stimulating the oncogenic pathways. Finally, this review collects the lessons from the previous unsuccessful trials and integrates their lessons with new approaches in RNA-modified dendritic cell vaccines. Unlike traditional approaches, the advances in single-cell RNA-sequencing techniques and RNA-modified dendritic cell vaccines along with combined therapy of the immune checkpoint inhibitors, indoleamine 2,3-dioxygenase inhibitor, and RNA-modified dendritic cell-based vaccine can overcome these auto-inductive loops and pave the way for developing robust dendritic cell-based vaccines with the most favorable response rate and the least side effects. |
topic |
dendritic cells immunotherapy melanoma development immune checkpoints IDO RNA-modified dendritic cell vaccines |
url |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.623639/full |
work_keys_str_mv |
AT mahdiabdolishadbad frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT mahdiabdolishadbad frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT khalilhajiasgharzadeh frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT afshinderakhshani frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT afshinderakhshani frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT nicolasilvestris frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT nicolasilvestris frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT amirbaghbanzadeh frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT vitoracanelli frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT behzadbaradaran frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast AT behzadbaradaran frommelanomadevelopmenttornamodifieddendriticcellvaccineshighlightingthelessonsfromthepast |
_version_ |
1724256994071674880 |